Xiang Zhou to Biomarkers, Tumor
This is a "connection" page, showing publications Xiang Zhou has written about Biomarkers, Tumor.
Connection Strength
0.625
-
Extracellular vesicle digital scoring assay for assessment of treatment responses in hepatocellular carcinoma patients. J Exp Clin Cancer Res. 2025 May 01; 44(1):136.
Score: 0.123
-
Noninvasive prognostication of hepatocellular carcinoma based on cell-free DNA methylation. PLoS One. 2025; 20(4):e0321736.
Score: 0.123
-
Comprehensive tissue deconvolution of cell-free DNA by deep learning for disease diagnosis and monitoring. Proc Natl Acad Sci U S A. 2023 07 11; 120(28):e2305236120.
Score: 0.109
-
cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution. Clin Cancer Res. 2022 05 02; 28(9):1841-1853.
Score: 0.100
-
Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis. Nat Commun. 2021 07 07; 12(1):4172.
Score: 0.095
-
HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma. Hepatology. 2023 03 01; 77(3):774-788.
Score: 0.026
-
Computational Analysis of High-Dimensional DNA Methylation Data for Cancer Prognosis. J Comput Biol. 2022 08; 29(8):769-781.
Score: 0.025
-
Early Diagnosis and Screening for Lung Cancer. Cold Spring Harb Perspect Med. 2021 09 01; 11(9).
Score: 0.024